Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey

Autor: Jorge Hernando, Teodora Kolarova, Chris Verslype, Gregory Kaltsas, Aude Houchard, Delphine Gueguen, Wouter W. De Herder
Přispěvatelé: Internal Medicine, Institut Català de la Salut, [Hernando J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Kolarova T] International Neuroendocrine Cancer Alliance, Boston, Massachusetts, USA. [Verslype C] University Hospital Gasthuisberg Leuven, Leuven, Belgium. [Kaltsas G] National and Kapodistrian University of Athens, Athens, Greece. [Houchard A, Gueguen D] Ipsen, Boulogne-Billancourt, France. [De Herder WW] Erasmus MC, Rotterdam, The Netherlands, Vall d'Hebron Barcelona Hospital Campus
Jazyk: angličtina
Rok vydání: 2023
Předmět:
neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos [ENFERMEDADES]
Endocrine and Autonomic Systems
Otros calificadores::/uso terapéutico [Otros calificadores]
Endocrinology
Diabetes and Metabolism
Pacients - Satisfacció
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]
Tumors neuroendocrins - Tractament
Somatostatina - Ús terapèutic
Other subheadings::Other subheadings::/drug therapy [Other subheadings]
hormonas
sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas peptídicas::hormonas hipotalámicas::hormonas inhibidoras de la liberación de hormonas hipofisarias::somatostatina [COMPUESTOS QUÍMICOS Y DROGAS]
Cellular and Molecular Neuroscience
Endocrinology
SDG 3 - Good Health and Well-being
Neoplasms::Neoplasms by Histologic Type::Neoplasms
Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors [DISEASES]
terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones [TÉCNICAS Y EQUIPOS ANALÍTICOS
DIAGNÓSTICOS Y TERAPÉUTICOS]
Other subheadings::/therapeutic use [Other subheadings]
Hormones
Hormone Substitutes
and Hormone Antagonists::Hormones::Peptide Hormones::Hypothalamic Hormones::Pituitary Hormone Release Inhibiting Hormones::Somatostatin [CHEMICALS AND DRUGS]
Therapeutics::Drug Therapy::Drug Administration Routes::Injections [ANALYTICAL
DIAGNOSTIC AND THERAPEUTIC TECHNIQUES
AND EQUIPMENT]
Zdroj: Journal of Neuroendocrinology. Wiley-Blackwell Publishing Ltd
Scientia
ISSN: 0953-8194
Popis: Injection experience; Neuroendocrine tumors; Somatostatin analog Experiència en injecció; Tumors neuroendocrins; Anàleg de la somatostatina Experiencia en inyección; Tumores neuroendocrinos; Análogo de la somatostatina Lanreotide autogel/depot (LAN) is a somatostatin analog used in first-line treatment for neuroendocrine tumors (NETs). The aim of HomeLAN was to evaluate the satisfaction with injection experience among patients with NETs receiving at-home LAN injection via patient support programs (PSPs). This was an international, non-interventional, cross-sectional, online survey in adults with NETs enrolled in PSPs, receiving LAN injections at home, administered by a healthcare professional (HCP) or administered independently (self or caregiver administering injection). The primary endpoint was satisfaction with the most recent LAN injection. Secondary endpoints included the level of anxiety prior to injection, impact on daily life, and the extents to which participants felt in control of their life and agreed that home administration met their medical needs. In total, 111 participants from Belgium, Greece, the Netherlands, and Spain completed the survey (50.5% male; mean age, 63.6 years; most common primary tumor site was intestine [47.7%]). For 99 participants, their most recent injection was administered by an HCP. Overall, 95.5% of all participants were satisfied with their most recent injection experience (95% confidence interval: 89.89%–98.06%); 67% reported experiencing no anxiety prior to injection, 91.0% reported that home injection had a “great deal” or “quite a bit” of positive impact on their daily life, and 85.6% strongly agreed that the PSP met their medical needs. In the HCP injection subgroup, 71.7% reported that this mode of administration helped them to feel in control of their lives. In this patient survey, satisfaction levels were high among patients with NETs receiving LAN injections at home via a LAN PSP. Most patients did not experience anxiety prior to their most recent injection and acknowledged that thanks to their treatment they had a good quality of life despite their disease. Most strongly agreed that the PSP met their medical needs, which highlights the valuable service that LAN PSPs provide for patients with NETs. This study was sponsored by Ipsen.
Databáze: OpenAIRE
Externí odkaz: